Skip to main contentSkip to navigationSkip to search

Curasight - Providing answers for cancer patients

Curasight technology

Play video

Latest Press Releases

SEB initiates commissioned research on Curasight A/S

June 18, 2021
 | Regulatory

Minutes from the Extraordinary General Meeting in Curasight A/S

June 1, 2021
 | Regulatory

Curasight presents at Bio Stock Life Science Spring Summit

May 26, 2021
 | Regulatory


Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.

Curasight – the company


Curasight builds its novel uPAR-PET imaging approach on a deep understanding of the uPAR system and it’s role in cancer, together with extensive experience with translational molecular imaging, which has been obtained through more than a decade of research at Rigshospitalet and University of Copenhagen.

Curasight’s technology


Curasight is focused on addressing the need for improved diagnosis and treatment of brain and prostate cancer. Curasight build on its foundation of pioneering research and development within uPAR-PET Imaging. Our clinical development efforts include a program to develop a first-in-class uPAR-PET imaging ligand which is currently in phase II clinical testing.

Curasight’s pipeline

Laboratory equipment

What is Molecular Nuclear Imaging?

Nuclear imaging uses trace amount of radioactive substances – called radiopharmaceuticals – to reveal specific biochemical processes. It is one of the fastest growing technologies in modern medicine.

Read more about Nuclear Medicine